Intellia Therapeutics (NTLA) Competitors $8.47 +0.19 (+2.29%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$8.60 +0.14 (+1.59%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. CRNX, VKTX, MOR, KYMR, SRRK, IMVT, MLTX, OGN, APLS, and HCMShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), MorphoSys (MOR), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Immunovant (IMVT), MoonLake Immunotherapeutics (MLTX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Crinetics Pharmaceuticals Viking Therapeutics MorphoSys Kymera Therapeutics Scholar Rock Immunovant MoonLake Immunotherapeutics Organon & Co. Apellis Pharmaceuticals HUTCHMED Intellia Therapeutics (NASDAQ:NTLA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Do insiders and institutionals hold more shares of NTLA or CRNX? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, NTLA or CRNX? Intellia Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Does the MarketBeat Community prefer NTLA or CRNX? Intellia Therapeutics received 290 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.43% of users gave Crinetics Pharmaceuticals an outperform vote while only 68.76% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes44968.76% Underperform Votes20431.24% Crinetics PharmaceuticalsOutperform Votes15969.43% Underperform Votes7030.57% Do analysts prefer NTLA or CRNX? Intellia Therapeutics currently has a consensus price target of $34.95, indicating a potential upside of 312.63%. Crinetics Pharmaceuticals has a consensus price target of $74.56, indicating a potential upside of 125.38%. Given Intellia Therapeutics' higher probable upside, research analysts clearly believe Intellia Therapeutics is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.67Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Is NTLA or CRNX more profitable? Crinetics Pharmaceuticals' return on equity of -36.12% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% Crinetics Pharmaceuticals N/A -36.12%-31.89% Does the media prefer NTLA or CRNX? In the previous week, Intellia Therapeutics had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 11 mentions for Intellia Therapeutics and 8 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.10 beat Intellia Therapeutics' score of 0.66 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, NTLA or CRNX? Crinetics Pharmaceuticals has lower revenue, but higher earnings than Intellia Therapeutics. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$45.57M19.25-$481.19M-$5.23-1.62Crinetics Pharmaceuticals$760K4,075.33-$214.53M-$3.82-8.66 SummaryCrinetics Pharmaceuticals beats Intellia Therapeutics on 10 of the 18 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$877.35M$2.69B$5.57B$8.67BDividend YieldN/A0.70%5.27%4.19%P/E Ratio-1.567.8327.2120.17Price / Sales19.2537.12414.99161.94Price / CashN/A15.7538.2534.64Price / Book0.725.727.124.72Net Income-$481.19M-$65.73M$3.23B$247.80M7 Day Performance10.43%2.04%3.80%2.76%1 Month Performance4.31%4.92%13.40%9.71%1 Year Performance-64.34%-19.97%32.04%14.51% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.6335 of 5 stars$8.47+2.3%$34.95+312.6%-63.6%$877.35M$45.57M-1.56600Analyst RevisionCRNXCrinetics Pharmaceuticals3.6147 of 5 stars$31.77+4.1%$74.56+134.7%-26.5%$2.96B$760,000.00-8.48210Positive NewsAnalyst RevisionVKTXViking Therapeutics4.4902 of 5 stars$26.14-2.5%$87.15+233.5%-48.3%$2.93BN/A-26.0920Options VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics2.0024 of 5 stars$43.09+45.4%$55.25+28.2%+41.9%$2.84B$58.89M-18.61170High Trading VolumeSRRKScholar Rock4.1288 of 5 stars$29.74+2.5%$42.67+43.5%+257.4%$2.82B$33.19M-12.63140IMVTImmunovant1.4482 of 5 stars$15.41+3.7%$38.33+148.8%-34.1%$2.62BN/A-5.88120Positive NewsAnalyst RevisionMLTXMoonLake Immunotherapeutics2.1615 of 5 stars$41.03+5.2%$78.71+91.9%+9.8%$2.60BN/A-31.482Analyst RevisionOGNOrganon & Co.4.9246 of 5 stars$9.22-0.1%$18.00+95.3%-51.5%$2.40B$6.29B2.7710,000Trending NewsAPLSApellis Pharmaceuticals4.6538 of 5 stars$19.11+12.9%$40.05+109.6%-53.0%$2.38B$775.84M-9.32770Analyst RevisionHCMHUTCHMED1.3353 of 5 stars$13.59-2.1%$19.00+39.8%-6.9%$2.36B$630.20M0.001,760Upcoming EarningsGap Up Related Companies and Tools Related Companies Crinetics Pharmaceuticals Alternatives Viking Therapeutics Alternatives MorphoSys Alternatives Kymera Therapeutics Alternatives Scholar Rock Alternatives Immunovant Alternatives MoonLake Immunotherapeutics Alternatives Organon & Co. Alternatives Apellis Pharmaceuticals Alternatives HUTCHMED Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
